The updated Medscheme specialised drug list for 2023 has been published
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Weight Loss: Advances in Hormone-Based Obesity Treatments
Advances in Hormone-Based Pharmacotherapies for Obesity
Hormone-based obesity treatments are improving the approach to weight management by targeting the body's neurometabolic systems. A recent
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
NICE's Unified Prioritization Roadmap
NICE NHS prioritization has led to a new, unified framework and board that will tackle emerging healthcare innovations while managing finite assessment capacity. The approach focuses on high-impact areas, including mental health, early cancer detect...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adult NF1 Patients
European Commission Approves Koselugo for Adult NF1 Patients
The European Commission has granted approval for Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, to treat symptomatic, inoperable plexiform neurofibromas in adult patients with neu...